---
title: China Insights | Regulatory Reform
description: Regulatory Reform | China insights and practical advice for global technology companies looking to do business in China's ever-changing market.
---

[Skip to content](https://www.adgchina.co/china-insights/tag/regulatory-reform#main-content)

[![ADGLogo-1](https://www.adgchina.co/hs-fs/hubfs/ADGLogo-1.png?width=168&height=85&name=ADGLogo-1.png)](https://adgchina.co)

- Solutions
  
  Show submenu for Solutions 
  
    - [China Growth Platform](https://www.adgchina.co/adg_growth_platform)
    - [Partnership Development](https://www.adgchina.co/en/technology-partnerships)
    - [China Advisory & Local Solutions](https://www.adgchina.co/china-market-services)
- Network
  
  Show submenu for Network 
  
    - [Partners](https://www.adgchina.co/ecosystem)
- [China Insights](https://www.adgchina.co/china-insights)
- [中文](https://china.adgchina.co/)

Open main navigation

Close main navigation

- Solutions
  
  Show submenu for Solutions 
  
    - [China Growth Platform](https://www.adgchina.co/adg_growth_platform)
    - [Partnership Development](https://www.adgchina.co/en/technology-partnerships)
    - [China Advisory & Local Solutions](https://www.adgchina.co/china-market-services)
- Network
  
  Show submenu for Network 
  
    - [Partners](https://www.adgchina.co/ecosystem)
- [China Insights](https://www.adgchina.co/china-insights)
- [中文](https://china.adgchina.co/)

 Let's Talk

[![China orphan drug regulations, magnifying glass over map of China, orphan drug vial, Shanghai skyline](https://www.adgchina.co/hubfs/china-orphan-drug-regulatory-reform-hero-final.jpeg)](https://www.adgchina.co/china-insights/chinas-new-exclusivity-rules-are-rewriting-orphan-drug-strategy)

### [China's New Exclusivity Rules Are Rewriting Orphan Drug Strategy](https://www.adgchina.co/china-insights/chinas-new-exclusivity-rules-are-rewriting-orphan-drug-strategy)

[Life Sciences](https://www.adgchina.co/china-insights/tag/life-sciences)[Market Entry](https://www.adgchina.co/china-insights/tag/market-entry)[China Biopharma](https://www.adgchina.co/china-insights/tag/china-biopharma)[Orphan Drugs](https://www.adgchina.co/china-insights/tag/orphan-drugs)[Clinical Development](https://www.adgchina.co/china-insights/tag/clinical-development)[Rare Disease](https://www.adgchina.co/china-insights/tag/rare-disease)[NMPA](https://www.adgchina.co/china-insights/tag/nmpa)[Regulatory Reform](https://www.adgchina.co/china-insights/tag/regulatory-reform)

Aug 5, 2026

Global pharma has treated China as a secondary market for rare disease drugs for a simple reason: th...

© 2026 ADG China

© 2026 ADG China